glp 1 in heart failure Mechanisms of GLP-1 Receptor Agonists HFpEF: Exploring Weight-Dependent and Independent Drivers of Therapeutic Benefit Epicardial Fat Paradox and Differential

Summary GLP-1 medications create wildly different outcomes depending on how patients manage details between doses, according to HealthVerity Blog's 2025 analysis of real-world data

The current regulatory environment is influenced by a September 2025 executive order aimed at enhancing transparency in DTC prescription drug advertising

With new guidance released by the Centers for Medicare & Medicaid Services, the episode explains how two upcoming federal programsthe Bridge Program (2026) and the Balance Model (2027)could expand access to medications like Zepbound and Wegovy

Guidelines currently recommend organ-specific management of obesity-related complications

doi: 10.3390/nu7021119 36

Contrary to expectations, zero-calorie drinks or diet soda appear ineffective and do not reduce the likelihood of developing T2D [60, 61]